Bevacizumab and cancer treatment-related mortality - Reply

Shenhong Wu; Vishal Ranpura; Sanjay Hapani

doi:10.1001/jama.2011.760

Bevacizumab and cancer treatment-related mortality - Reply

Shenhong Wu
, Vishal Ranpura
, Sanjay Hapani

Medical Oncology

Stony Brook University

Stony Brook University

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2292-2293
Number of pages	2
Journal	JAMA
Volume	305
Issue number	22
DOIs	https://doi.org/10.1001/jama.2011.760
State	Published - Jun 8 2011

Access to Document

10.1001/jama.2011.760

Cite this

@article{08da470dc2644a04847e07e17f56a10c,

title = "Bevacizumab and cancer treatment-related mortality - Reply",

author = "Shenhong Wu and Vishal Ranpura and Sanjay Hapani",

year = "2011",

month = jun,

day = "8",

doi = "10.1001/jama.2011.760",

language = "English",

volume = "305",

pages = "2292--2293",

journal = "JAMA",

issn = "0098-7484",

number = "22",

}

TY - JOUR

T1 - Bevacizumab and cancer treatment-related mortality - Reply

AU - Wu, Shenhong

AU - Ranpura, Vishal

AU - Hapani, Sanjay

PY - 2011/6/8

Y1 - 2011/6/8

UR - https://www.scopus.com/pages/publications/79958024027

U2 - 10.1001/jama.2011.760

DO - 10.1001/jama.2011.760

M3 - Letter

C2 - 21642678

SN - 0098-7484

VL - 305

SP - 2292

EP - 2293

JO - JAMA

JF - JAMA

IS - 22

ER -

Bevacizumab and cancer treatment-related mortality - Reply

Access to Document

Other files and links

Fingerprint

Cite this